Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner

Antiviral Research

Volumn 109, Issue 1, 2014, Pages 7-14

  De Nicolò, Amedeo ^a   Boglione, Lucio ^a   Ciancio, Alessia ^a   Cusato, Jessica ^a   Strona, Silvia ^a   Cardellino, Chiara Simona ^a   Mohamed Abdi, Adnan ^a   Cariti, Giuseppe ^a   Troshina, Giulia ^a   Caviglia, Gian Paolo ^a   Smedile, Antonina ^a   Rizzetto, Mario ^a   Di Perri, Giovanni ^a   D'Avolio, Antonio ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Anaemia; HCV 1; Interaction; Ribavirin; Telaprevir

Indexed keywords

HEMOGLOBIN; RIBAVIRIN; TELAPREVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; OLIGOPEPTIDE;

ADULT; ARTICLE; DRUG BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HEMOLYTIC ANEMIA; HUMAN; ISOMER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; ADVERSE EFFECTS; CHEMICALLY INDUCED; CHEMISTRY; CONTROLLED STUDY; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOMERISM; MIDDLE AGED; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; VIROLOGY;

ADULT; ANEMIA, HEMOLYTIC; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; ISOMERISM; MALE; MIDDLE AGED; OLIGOPEPTIDES; RIBAVIRIN;

EID: 84903942728     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.06.005     Document Type: Article

References (34)

1. Asselah, T., Pasmant, E., Lyoumi, S., 2010. Unraveling the genetic predisposition of ribavirin-induced anaemia. J Hepatol.
2. L. Boglione, A. De Nicolo, J. Cusato, G. Cariti, G. Di Perri, and A. D'Avolio Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir J. Viral. Hepat. 21 2014 260 263
3. G. Caviglia, A. D'Avolio, A. Ciancio, A. De Nicolò, L. Boglione, M. Abate, C. Rosso, A. Smedile, G. Cariti, and J. Cusato F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy Digest. Liver Dis. 44 2012 S42
4. E.Y. Chen, S.N. Sclair, F. Czul, B. Apica, P. Dubin, P. Martin, and W.M. Lee A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir Clin. Gastroenterol. Hepatol. 11 2013 1014 1020 (e1012)
5. A. D'Avolio, A. Ciancio, M. Siccardi, L. Baietto, M. Simiele, G. Cariti, A. Calcagno, A. Smedile, J. Cusato, S. Bonora, M. Rizzetto, and G. Di Perri Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4 Hepatology 54 2011 2279
6. A. D'Avolio, A. Ciancio, M. Siccardi, A. Smedile, L. Baietto, M. Simiele, D.A. Marucco, G. Cariti, A. Calcagno, D.G. de Requena, M. Sciandra, J. Cusato, G. Troshina, S. Bonora, M. Rizzetto, and G. Di Perri Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment Ther. Drug Monit. 34 2012 165 170
7. A. D'Avolio, J. Cusato, A. Calcagno, and G. Di Perri Estimating ribavirin plasma exposure: genetics or therapeutic drug monitoring? J. Hepatol. 59 2013 633 634
8. D'Avolio, A., De Nicolo, A., Agnesod, D., Simiele, M., Mohamed Abdi, A., Dilly Penchala, S., Boglione, L., Cariti, G., Di Perri, G., 2013b. A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir. J Pharm Biomed Anal 78-79, 217-223.
9. A. D'Avolio, A. De Nicolo, J. Cusato, A. Ciancio, L. Boglione, S. Strona, G. Cariti, G. Troshina, G.P. Caviglia, A. Smedile, M. Rizzetto, and G. Di Perri Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients Antiviral Res. 100 2013 114 119
10. A. D'Avolio, A. De Nicolo, M. Simiele, S. Turini, D. Agnesod, L. Boglione, J. Cusato, L. Baietto, G. Cariti, A. Calcagno, M. Sciandra, G. Di Perri, and S. Bonora Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients J. Pharm. Biomed. Anal. 66 2012 376 380
11. A. D'Avolio, A. Ibanez, M. Sciandra, M. Siccardi, D.G. de Requena, S. Bonora, and G. Di Perri Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 835 2006 127 130
12. L. De Franceschi, G. Fattovich, F. Turrini, K. Ayi, C. Brugnara, F. Manzato, F. Noventa, A.M. Stanzial, P. Solero, and R. Corrocher Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage Hepatology 31 2000 997 1004 (Pubitemid 30169949)
13. A. De Nicolò, J. Cusato, L. Boglione, A. Ciancio, A. Smedile, D. Agnesod, G. Cariti, M. Rizzetto, G. Di Perri, and A. D'Avolio P-21 Early ribavirin plasma concentrations as predictor of anemia onset after one month of anti-HCV therapy in ITPA stratified population Rev. Antiviral Ther. Infect. Dis. 3 2013 51
14. A. De Nicolò, J. Cusato, L. Boglione, F. Patti, A. Ciancio, A. Smedile, D. Agnesod, G. Cariti, M. Rizzetto, G. Di Perri, and A. D'Avolio O-18 Early ribavirin concentration is a critical response factor in the sub-population of patients infected by HCV-1 and unfavourable IL28B genotype Rev. Antiviral Ther. Infect. Dis. 3 2013 21
15. Fukuda, K., Imai, Y., Hiramatsu, N., Irishio, K., Igura, T., Sawai, Y., Kogita, S., Makino, Y., Mizumoto, R., Matsumoto, Y., Nakahara, M., Zushi, S., Kajiwara, N., Oze, T., Kawata, S., Hayashi, N., Takehara, T., 2013. Renal impairment during the treatment of telaprevir with peginterferon and ribavirin in patients with chronic hepatitis C. Hepatol Res.
16. N. Furusyo, E. Ogawa, M. Murata, K. Toyoda, H. Ohnishi, K. Eiraku, M. Shimizu, Y. Harada, F. Mitsumoto, K. Takayama, M. Kainuma, K. Okada, and J. Hayashi Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response J. Antimicrob. Chemother. 69 2014 483 490
17. M.G. Ghany, D.R. Nelson, D.B. Strader, D.L. Thomas, and L.B. Seeff An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases Hepatology 54 2011 1433 1444
18. D. Gonzalez de Requena, A. Calcagno, S. Bonora, L. Ladetto, A. D'Avolio, M. Sciandra, M. Siccardi, O. Bargiacchi, A. Sinicco, and G. Di Perri Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide AIDS 20 2006 1977 1979 (Pubitemid 44427617)
19. K. Hammond, L. Jimmerson, C. MacBrayne, M. Ray, L. Bushman, J. Burton, F. Baouchi-Mokrane, G. Everson, P. Anderson, and J. Kiser PP-02 increased plasma and intracellular ribavirin concentrations associated with telaprevir use Rev. Antiviral Ther. Infect. Dis. 3 2013 26
20. C. Hezode Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice Liver Int. 32 Suppl. 1 2012 32 38
21. C. Hezode, N. Forestier, G. Dusheiko, P. Ferenci, S. Pol, T. Goeser, J.P. Bronowicki, M. Bourliere, S. Gharakhanian, L. Bengtsson, L. McNair, S. George, T. Kieffer, A. Kwong, R.S. Kauffman, J. Alam, J.M. Pawlotsky, and S. Zeuzem Telaprevir and peginterferon with or without ribavirin for chronic HCV infection N. Engl. J. Med. 360 2009 1839 1850
22. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, N.H. Bzowej, P. Marcellin, A.J. Muir, P. Ferenci, R. Flisiak, J. George, M. Rizzetto, D. Shouval, R. Sola, R.A. Terg, E.M. Yoshida, N. Adda, L. Bengtsson, A.J. Sankoh, T.L. Kieffer, S. George, R.S. Kauffman, and S. Zeuzem Telaprevir for previously untreated chronic hepatitis C virus infection N. Engl. J. Med. 364 2011 2405 2416
23. Karino, Y., Ozeki, I., Hige, S., Kimura, M., Arakawa, T., Nakajima, T., Kuwata, Y., Sato, T., Ohmura, T., Toyota, J., 2013. Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C. J Viral Hepat.
24. C.C. Lin, and M.C. Yin Vitamins B depletion, lower iron status and decreased antioxidative defense in patients with chronic hepatitis C treated by pegylated interferon alfa and ribavirin Clin. Nutr. 28 2009 34 38
25. S. Mauss, D. Hueppe, and U. Alshuth Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir Hepatology 59 2014 46 48
26. J.G. McHutchison, M.P. Manns, and D.L. Longo Definition and management of anemia in patients infected with hepatitis C virus Liver Int. 26 2006 389 398
27. Reesink, H.W., Zeuzem, S., Weegink, C.J., Forestier, N., van Vliet, A., van de Wetering de Rooij, J., McNair, L., Purdy, S., Kauffman, R., Alam, J., Jansen, P.L., 2006. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 131, 997-1002. (Pubitemid 44498690)
28. M. Romero-Gomez, M. Berenguer, E. Molina, and J.L. Calleja Management of anemia induced by triple therapy in patients with chronic hepatitis C: challenges, opportunities and recommendations J. Hepatol. 59 2013 1323 1330
29. Ronzoni, L., Aghemo, A., Rumi, M.G., Prati, G., Colancecco, A., Porretti, L., Monico, S., Colombo, M., Cappellini, M.D., 2013. Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients. J Viral Hepat.
30. K.E. Sherman, S.L. Flamm, N.H. Afdhal, D.R. Nelson, M.S. Sulkowski, G.T. Everson, M.W. Fried, M. Adler, H.W. Reesink, M. Martin, A.J. Sankoh, N. Adda, R.S. Kauffman, S. George, C.I. Wright, and F. Poordad Response-guided telaprevir combination treatment for hepatitis C virus infection N. Engl. J. Med. 365 2011 1014 1024
31. Y. Tanaka, M. Kurosaki, N. Nishida, M. Sugiyama, K. Matsuura, N. Sakamoto, N. Enomoto, H. Yatsuhashi, S. Nishiguchi, K. Hino, S. Hige, Y. Itoh, E. Tanaka, S. Mochida, M. Honda, Y. Hiasa, A. Koike, F. Sugauchi, S. Kaneko, N. Izumi, K. Tokunaga, and M. Mizokami Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C Hum. Mol. Genet. 20 2011 3507 3516
32. Tempestilli, M., D'Offizi, G., Lionetti, R., Montalbano, M., Giaffreda, A., Fazio, S., Pucillo, L.P., 2013. Increased plasma concentration of Ribavirin as a result of renal dysfunction in HCV patients treated with telaprevir. Hepatology.
33. J. Toyota, I. Ozeki, Y. Karino, Y. Asahina, N. Izumi, S. Takahashi, Y. Kawakami, K. Chayama, N. Kamiya, K. Aoki, I. Yamada, Y. Suzuki, F. Suzuki, and H. Kumada Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b J. Viral. Hepat. 20 2013 167 173
34. Telaprevir for retreatment of HCV infection